Authors' recommendations: An OncotypeDX (ODX) recurrence score aims to (a) provide prognosis with respect to 10-year recurrence of breast cancer, and (b) guide the need for adjuvant chemotherapy (ACT) treatment. The evidence base for the use of ODX in women with ER+ HER2- LN- early stage breast cancer (ESBC) to guide ACT treatment decisions includes four recent examples of secondary research (health technology assessments [HTAs] and systematic reviews [SRs]) and four additional primary studies. There is no evidence related specifically to men. Results consistently show about 30% of treatment plans are affected, primarily being lower rates of ACT for patients determined to be at low recurrence risk. For a smaller proportion determined to be at higher risk, ACT is suggested where initial treatment planning did not include ACT. The most uncertainty relates to the intermediate risk category where evidence is unclear; a large 7-country study (TAILORx) is focussing on the treatment of this group with study completion planned for late 2017.

Project Status: Completed

Year Published: 2014

URL for published report: http://www.cadth.ca/media/pdf/htis/apr-2014/RC0524%20Oncotype%20DX%20for%20node%20negative%20patients%20Final.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)